PUBLIC DISCLOSURE & CLARIFICATION

BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.

CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.

Src inhibitor KX2-391, Purity ≥98%

Inquiry

Cat. No.: X24-06-ZQ339

Src inhibitor KX2-391, Purity ≥98%

Synonym: 897016-82-9; Src inhibitor; KX2391

CAS Number: 897016-82-9
Compound CID: 23635314

Product Size

5 mg; 10 mg; 50 mg; 100 mg

Price

Datasheet

MSDS

Properties

Description

KX2-391, soluble in DMSO and insoluble in ethanol and water, blocks the activity of Src kinases, which are involved in various cellular processes such as growth, differentiation, and survival, and have been implicated in the progression of several cancers and other diseases. It targets Src (Hep 3B), Src (Hep G2), Src (HuH7), and Src (PLC/PRF/5).

Molecular Weight

431.53

Molecular Formula

C₂₆H₂₉N₃O₃

Targets

Src (Hep 3B): 26 nM (GI₅₀); Src (Hep G2): 60 nM (GI₅₀); Src (HuH7): 9 nM (GI₅₀); Src (PLC/PRF/5): 13 nM (GI₅₀)

Form

Lyophilized powder

Purity

Solubility

DMSO: 77 mg/mL (178.43 mM); Water: Insoluble; Ethanol: Insoluble

Identity

Confirmed by NMR/HPLC/MS.

Applications

KX2-391 is used to research its role in inhibiting Src, laying the groundwork for potential cancer therapies targeting this kinase.

Publications

Publications (0)

Publications

Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.